RNTX
Rein Therapeutics Inc.
There isn't enough reported data to score RNTX yet.
RNTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RNTX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
RNTX PE Valuation
RNTX has no meaningful PE right now: it lost money over the past year.
RNTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect RNTX's losses to shrink, with revenue holding steady.
RNTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.72 | +$1.01 |
| Q1 2026 | -$1.90 | +$1.00 |
| Q4 2025 | -$1.96 | +$1.55 |
| Q3 2025 | -$2.67 | +$0.49 |
| Q2 2025 | -$2.73 | +$0.56 |
| Q1 2025 | -$2.90 | +$0.33 |
| Q4 2024 | -$3.51 | -$0.09 |
| Q3 2022 | -$6.60 | $0.00 |
RNTX is still losing money, but far less than before: $1.72 per share over the past year, against $30.20 at its worst in late 2019.
RNTX Quarterly Revenue
RNTX's revenue is shrinking: $0 last quarter.
RNTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$8.6M | -$2.2M |
| Q1 2026 | -$3.4M | +$2.8M |
| Q4 2025 | -$3.2M | +$1.6M |
| Q3 2025 | -$3.5M | +$271K |
| Q2 2025 | -$6.4M | +$2M |
| Q1 2025 | -$6.2M | -$904K |
| Q4 2024 | -$4.8M | +$5.6M |
| Q3 2024 | -$3.8M | -$2.2M |
RNTX has burned cash in almost every quarter: −$19M over the past year, against −$21M the year before.
RNTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +121% | +36.7M shares |
| 1 year | +177% | +42.9M shares |
| 3 years | +1377% | +62.5M shares |
| 5 years | +1383% | +62.6M shares |
| Available history | +4724% | +65.7M shares |
RNTX has 67M diluted shares, up 177% from a year ago.
RNTX Net Leverage
RNTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RNTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 17.7 | Oversold |
RNTX's weekly RSI is 36 (neutral) and its Stochastic is 18 (oversold).
RNTX PE vs Healthcare Sector
RNTX has no meaningful PE right now: it lost money over the past year.
RNTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.67 | 16% below |
| 20 week MA | $0.77 | 27% below |
| 50 week MA | $1.04 | 46% below |
| 100 week MA | $1.37 | 59% below |
| 200 week MA | $2.07 | 73% below |
RNTX is in a downtrend: it's below all five of its weekly moving averages, and 73% below its 200-week average.
RNTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.4 | $22.6 | +82% |
| 2021 | $22.6 | $11.4 | -50% |
| 2022 | $11.4 | $2.26 | -80% |
| 2023 | $2.26 | $3.05 | +35% |
| 2024 | $3.05 | $2.23 | -27% |
| 2025 | $2.23 | $1.24 | -44% |
| 2026 YTD | $1.24 | $0.56 | -55% |
RNTX has finished lower in four of the last six years. It's down 55% so far in 2026.